JOURNAL ARTICLE
Posterior subtenon triamcinolone, intravitreal triamcinolone and grid laser photocoagulation for the treatment of macular edema in branch retinal vein occlusion.
Ophthalmic Research 2008
PURPOSE: To evaluate the efficacy of posterior subtenon triamcinolone (PSTT), intravitreal triamcinolone (IVT) injections and grid laser photocoagulation (GLP) in eyes with macular edema secondary to branch retinal vein occlusion (BRVO).
MATERIAL AND METHODS: Patients with macular edema due to BRVO treated with PSTT, IVT injections or GLP were evaluated retrospectively. Complete ophthalmic examination with fluorescein angiography and optic coherence tomography were noted before and in the 1st, 3rd, and 6th months of the treatment. The visual and anatomical responses were evaluated and compared between the groups using paired t test and one-way ANOVA test.
RESULTS: There were 20, 35 and 24 eyes in the PSTT, IVT and GLP groups. In the PSTT group, the mean visual acuity (VA) and central foveal thickness (CFT) were 0.23 +/- 0.23 and 413.2 +/- 143.5 microm before treatment and 0.23 +/- 0.18 and 358.7 +/- 109.2 microm at the 3rd month, respectively (p = 0.504 and p = 0.031). The mean VA increased from 0.14 +/- 0.15 to 0.33 +/- 0.26 and the mean CFT decreased from 518.2 +/- 145 to 292.9 +/- 121 microm in IVT group at the 3rd month (p = 0.001). The mean VA increased from 0.29 +/- 0.25 to 0.47 +/- 0.32 (p = 0.001); CFT decreased from 397.3 +/- 105.9 to 307.1 +/- 88.4 microm (p = 0.005) in the GLP group. VA and CFT changes were significantly different between the groups at the 3rd month (p = 0.031). VA increase was significantly greater in the IVT group than in the PSTT group. Decrease in CFT was the highest in the IVT group (Tukey, p = 0.001).
CONCLUSIONS: IVT and GLP seemed to be more effective than PSTT for the treatment of BRVO-associated macular edema. Possible complications of IVT and GLP must be weighted with the advantages of each treatment modality for each patient.
MATERIAL AND METHODS: Patients with macular edema due to BRVO treated with PSTT, IVT injections or GLP were evaluated retrospectively. Complete ophthalmic examination with fluorescein angiography and optic coherence tomography were noted before and in the 1st, 3rd, and 6th months of the treatment. The visual and anatomical responses were evaluated and compared between the groups using paired t test and one-way ANOVA test.
RESULTS: There were 20, 35 and 24 eyes in the PSTT, IVT and GLP groups. In the PSTT group, the mean visual acuity (VA) and central foveal thickness (CFT) were 0.23 +/- 0.23 and 413.2 +/- 143.5 microm before treatment and 0.23 +/- 0.18 and 358.7 +/- 109.2 microm at the 3rd month, respectively (p = 0.504 and p = 0.031). The mean VA increased from 0.14 +/- 0.15 to 0.33 +/- 0.26 and the mean CFT decreased from 518.2 +/- 145 to 292.9 +/- 121 microm in IVT group at the 3rd month (p = 0.001). The mean VA increased from 0.29 +/- 0.25 to 0.47 +/- 0.32 (p = 0.001); CFT decreased from 397.3 +/- 105.9 to 307.1 +/- 88.4 microm (p = 0.005) in the GLP group. VA and CFT changes were significantly different between the groups at the 3rd month (p = 0.031). VA increase was significantly greater in the IVT group than in the PSTT group. Decrease in CFT was the highest in the IVT group (Tukey, p = 0.001).
CONCLUSIONS: IVT and GLP seemed to be more effective than PSTT for the treatment of BRVO-associated macular edema. Possible complications of IVT and GLP must be weighted with the advantages of each treatment modality for each patient.
Full text links
Trending Papers
Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology.Swiss Medical Weekly 2023 January 7
Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment.Frontiers in Immunology 2022
Migraine.Annals of Internal Medicine 2023 January 11
Long COVID: major findings, mechanisms and recommendations.Nature Reviews. Microbiology 2023 January 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app